Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin

Completed · Phase 2

Conditions studied: Ovarian Cancer, Testicular Germ Cell Tumor

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have metastatic germ cell tumors that have not responded to cisplatin.

Key facts

Study ID

NCT00006043

Run by

Memorial Sloan Kettering Cancer Center

Starts

2000-02-01

Expected to finish

2001-11-01

Last updated by the study team

2013-06-05

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.